慢性丙型肝炎抗病毒治疗中的甲状腺功能障碍

Thyroid dysfunction in antiviral therapy of chronic hepatitis C.

作者信息

Dabrowska Magdalena M, Panasiuk Anatol, Flisiak Robert

机构信息

Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 14 Zurawia Str, 15-540 Bialystok, Poland.

出版信息

Hepatogastroenterology. 2010 Jul-Aug;57(101):826-31.

PMID:21033237

Abstract

BACKGROUND/AIMS: Thyroid disorders are common dysfunctions during HCV infection and IFN-therapy. The aim of the study was to evaluate the general risk of thyroid disorders' development in chronic HCV-infected patients and their possible relationship with HCV genotype, type of used IFN-alpha and viral response.

METHODOLOGY

A study was performed in 89 patients with chronic hepatitis C (57 males, 32 females) and 25 healthy subjects. All HCV-infected patients were treated by IFN-alpha and RBV for a period depending on the HCV genotype. Hematological parameters, liver and thyroid function tests were analyzed. Serum Tpo-Ab and TG-Ab were detected by semiquantitative ELISA. In statistical analyses U Mann-Whitney and Spearman correlation tests were used. Ap value < 0.05 was considered significant.

RESULTS

Twelve (13.5%) CHC patients developed thyroid disorders during IFN-alpha therapy. Thyroid disorders were more often detected in females, in 3a-genotype-infection and in patients treated with natural leukocyte IFN-alpha. Seven (7.6%) Tpo-Ab and/or TG-Ab positive patients were noticed. Four of them (57.1%) developed hypothyroidism during IFN-alpha therapy.

CONCLUSION

This study demonstrated low effect of IFN-alpha therapy on thyroid disorders development and on TPO-Ab and TG-Ab serum level in chronic HCV-infected patients.

摘要

背景/目的：甲状腺功能紊乱是丙型肝炎病毒（HCV）感染及干扰素治疗期间常见的功能障碍。本研究旨在评估慢性HCV感染患者发生甲状腺功能紊乱的总体风险及其与HCV基因型、所用α干扰素类型和病毒应答的可能关系。

方法

对89例慢性丙型肝炎患者（57例男性，32例女性）和25例健康受试者进行了研究。所有HCV感染患者均根据HCV基因型接受α干扰素和利巴韦林治疗一段时间。分析血液学参数、肝脏和甲状腺功能测试。采用半定量酶联免疫吸附测定法检测血清甲状腺过氧化物酶抗体（Tpo-Ab）和甲状腺球蛋白抗体（TG-Ab）。统计分析采用U曼-惠特尼检验和斯皮尔曼相关性检验。P值<0.05被认为具有统计学意义。